Sophiris Bio Quick Ratio (SPHS) starting from the third quarter 2019 to third quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sophiris Bio Inc.  (SPHS)

Sophiris Bio's Quick Ratio

SPHS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Sophiris Bio's Cash & cash equivalent grew by 4.72 % in the Q3 2019 sequentially, while Current Liabilities decreased, this led to improvement in Sophiris Bio's Quick Ratio to 1.64, Quick Ratio remained below Sophiris Bio Inc. average.

Within Major Pharmaceutical Preparations industry 353 other companies have achieved higher Quick Ratio than Sophiris Bio in third quarter 2019. While Quick Ratio total ranking in the third quarter 2019 has deteriorated compared to the prior quarter from 940 to 1403.

Explain Quick Ratio?
How much Cash & cash equivalents SPHS´s has?
What are SPHS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SPHS Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3
Y / Y Current Liabilities Change 3.53 % -20.31 % 17.4 % 84.02 % 67.04 %
Y / Y Cash & cash equivalent Change -56.68 % -67.52 % -59.1 % -51.48 % -48.98 %
Quick Ratio MRQ 1.64 1.38 1.96 2.52 3.92
SPHS's Total Ranking # 1403 # 940 # 1206 # 876 # 652
Seq. Current Liabilities Change -12.07 % -4.94 % -7.62 % 34.07 % -32.31 %
Seq. Cash & cash equivalent Change 4.72 % -33.29 % -28.06 % -13.8 % -21.49 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 354
Healthcare Sector # 591
Overall Market # 1403


Quick Ratio Statistics
High Average Low
22.84 6.02 0.93
(Mar 31 2017)   (Dec 31 2012)




Financial Statements
Sophiris Bio's Current Liabilities $ 4 Millions Visit SPHS's Balance sheet
Sophiris Bio's Cash & cash equivalent $ 6 Millions Visit SPHS's Balance sheet
Source of SPHS's Sales Visit SPHS's Sales by Geography


Cumulative Sophiris Bio's Quick Ratio

SPHS's Quick Ratio for the trailling 12 Months

SPHS Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth 12.46 % 23.24 % 78.7 % 134.52 % 118.74 %
Y / Y Cash & cash equivalent TTM Growth -58.16 % -55.63 % -45.61 % -34.99 % -24.49 %
Quick Ratio TTM 1.91 2.39 2.91 3.74 5.12
Total Ranking TTM # 4583 # 839 # 539 # 4358 # 4216
Seq. Current Liabilities TTM Growth 0.74 % -5.93 % 3.77 % 14.37 % 10.4 %
Seq. Cash & cash equivalent TTM Growth -19.57 % -22.9 % -19.26 % -16.43 % -14.71 %

Quick ratio ranking by company, industry and sector >> Back to SPHS Financial Strength Comparisons >> Go to Compare SPHS Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q3 2019 to $3.84 millions, cumulative Quick Ratio decreased to 1.91 below the Sophiris Bio Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 461 other companies have achieved higher Quick Ratio than Sophiris Bio. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 839 to 4583.

Explain Quick Ratio?
How much Cash & cash equivalents SPHS´s has?
What are SPHS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 462
Healthcare Sector # 895
Within the Market # 4583


trailing twelve months Quick Ratio Statistics
High Average Low
15.78 6.2 1.87
(Jun 30 2017)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Protagonist Therapeutics inc   4.47 $ 137.692  Millions$ 30.776  Millions
Cellectar Biosciences Inc   4.47 $ 13.302  Millions$ 2.978  Millions
Prophase Labs Inc   4.41 $ 4.728  Millions$ 1.073  Millions
Merrimack Pharmaceuticals Inc  4.40 $ 20.858  Millions$ 4.739  Millions
Immunic Inc   4.33 $ 30.460  Millions$ 7.036  Millions
Cytomx Therapeutics Inc   4.28 $ 325.713  Millions$ 76.126  Millions
Phio Pharmaceuticals Corp  4.28 $ 8.709  Millions$ 2.036  Millions
Catalyst Pharmaceuticals Inc   4.26 $ 76.545  Millions$ 17.982  Millions
Esperion Therapeutics Inc   4.24 $ 243.861  Millions$ 57.518  Millions
Tonix Pharmaceuticals Holding Corp   4.24 $ 10.024  Millions$ 2.366  Millions
Optinose Inc   4.19 $ 125.490  Millions$ 29.962  Millions
China Health Industries Holdings Inc   4.18 $ 34.981  Millions$ 8.362  Millions
Neubase Therapeutics inc   4.12 $ 10.314  Millions$ 2.502  Millions
Regenerx Biopharmaceuticals inc   4.03 $ 0.882  Millions$ 0.219  Millions
Rezolute Inc   4.01 $ 22.139  Millions$ 5.523  Millions
Tvardi Therapeutics Inc   4.00 $ 193.089  Millions$ 48.299  Millions
Societal Cdmo Inc   3.96 $ 37.944  Millions$ 9.573  Millions
Syndax Pharmaceuticals Inc   3.95 $ 72.339  Millions$ 18.294  Millions
Anixa Biosciences Inc   3.94 $ 5.842  Millions$ 1.481  Millions
Xoma Royalty Corporation  3.94 $ 39.744  Millions$ 10.089  Millions
Ptc Therapeutics inc   3.86 $ 708.649  Millions$ 183.500  Millions
Horizon Therapeutics Public Limited Company  3.84 $ 887.710  Millions$ 231.070  Millions
Inhibitor Therapeutics Inc   3.82 $ 1.372  Millions$ 0.359  Millions
Rein Therapeutics Inc   3.82 $ 24.561  Millions$ 6.428  Millions
Dynavax Technologies Corporation  3.77 $ 174.946  Millions$ 46.348  Millions
Viracta Therapeutics Inc   3.69 $ 32.813  Millions$ 8.894  Millions
Ovid Therapeutics Inc   3.67 $ 38.021  Millions$ 10.361  Millions
Novabridge Biosciences  3.61 $ 167.985  Millions$ 46.475  Millions
Kyto Technology And Life Science Inc   3.61 $ 0.238  Millions$ 0.066  Millions
Chembio Diagnostics Inc   3.53 $ 21.868  Millions$ 6.187  Millions

Date modified: 2026-09-26T07:05:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.